New Partnership in Russia and CIS Further Expands Footprint for EffRx Proprietary Technologies

Freienbach, Switzerland, January 13, 2015 – EffRx Pharmaceuticals SA, a specialty pharmaceutical company focused on the development of novel therapeutic entities for a variety of orphan and specialty indications, today announced the signing of an agreement with Andrus Ltd. to develop products for commercialization in Russia and CIS countries.

“We are excited to further expand the footprint of our proprietary technologies with the development of novel therapeutic entities for these fast-growing emerging markets” said Christer Rosén, EffRx Chief Executive Officer. “Although our core focus within EffRx is to develop our own un-encumbered orphan products we will still utilize this business segment to generate a steady increasing revenue stream.”

Under the terms of the agreement EffRx will develop novel, tailored therapeutic entities (6 products are presently identified) for commercialization by Andrus in Russia and CIS countries. “We are excited to expand our partnership with Andrus beyond our earlier agreement with Binosto®, our first approved product for osteoporosis, and to bring new products that will address an unmet medical need in these countries” said Christer Rosén.

—————————————————

About EffRx Pharmaceuticals
EffRx Pharmaceuticals is an innovative specialty pharmaceutical company that develops novel therapeutic entities including orphan indications by applying its proprietary technology platform to well characterized molecules. EffRx developments focus at improving the quality of life of patients with unmet medical needs.

About Andrus Ltd.
Andrus Ltd. is dedicated to creating a novel Russian biopharmaceutical platform by bridging the gap between novel biopharmaceutical technologies and the Russian Healthcare market. Through partnering with leading development companies and leveraging Andrus’ domestic operations, the Company is able to build a healthcare platform based on best in class science and drug development.